biOasis Appoints Doug Williams, MBA, EVP, CBO Please contact myself or Catherine if you have any questions.
Graeme
investors@bioasis.us
+1 403 561 8989
Catherine
catherine@bioasis.us
+1 917 763 2709
____________________________
biOasis Appoints Doug Williams, MBA, Executive Vice President,
Chief Business Officer
Williams bring significant experience in working with both large, multinational pharmaceutical
companies & start-up biotechnology alliances
August 21, 2017, Vancouver, BC
VANCOUVER, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Doug Williams,
MBA, as executive vice president, chief business officer, effective immediately. Williams will report to
Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, Williams
will provide leadership and execute on the corporate development strategy that will maximize benefits
for strategic partners and shareholders. Williams will be responsible for leading corporate and business
development, as well as the alliance management efforts at biOasis.
"We are delighted to welcome Doug Williams to our senior management team at biOasis. I know he will
bring value as a business development leader and well-respected and strategic alliance professional,"
said Dr. Day. "Doug will play a critical role in advancing our partnering strategy and create value through
the prosecution of licensing opportunities for our proprietary blood-brain barrier drug delivery
platform."
Williams has more than 20 years of experience in the pharmaceutical and healthcare industries and has
successfully led cross-functional, global alliances teams across multiple organizations. His alliance and
partnering experience includes a broad set of partners including large, multinational pharmaceutical
companies, as well as start-up biotechnology companies, which included global alliances with Shionogi,
Exicure, AbbVie, Mylan and Takeda, among others.
Williams has been recognized as an industry leader who has presented, participated as a panelist, and
moderated multiple industry partnering programs at industry events.
"Doug has a broad set of experiences having worked in leadership roles at healthcare technology startups,
pharmaceutical and biotechnology companies. His diverse experience base will help propel our
global partnering efforts," said Rob Hutchison, founder and chairman of the board of directors. "Doug
will be a great addition to the biOasis leadership team."
Williams most recently came from Purdue Pharma L.P where he worked on strategic alliances and
business development projects related to clinical and pre-clinical programs. Prior to Purdue, Williams
built his own successful consulting business working with start-up healthcare technology companies.
Doug’s experience includes commercial sales, sales management, alliance management and business
development. He has also held various positions of increasing responsibility at Pfizer, Johnson &
Johnson, Elan, Sepracor and Kadmon over his 20 year career.
"I am eager to work with Mark on shaping the business strategy for biOasis as we continue to advance
our proprietary blood-brain barrier technology platform,” said Williams. “I want to thank Rob and Mark
for this opportunity. I look forward to sharing the biOasis story with new potential collaborators and
leading the licensing and partnering efforts on behalf of the company and our shareholders."
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of
therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the
BBB represents the single greatest challenge in treating neurological disorders. The company is
developing and commercializing a proprietary brain delivery technology to address unmet medical
needs in the treatment of central nervous system diseases and disorders. The company maintains
headquarters in Vancouver, Canada with offices in Connecticut, United States. biOasis trades on the
OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more
information about the company please visit www.bioasis.ca.
Forward-Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical fact, including without limitation
statements containing the words "believe," "may," "plan," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions. Such forward-looking statements or information involve
known and unknown risks, uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future results, events or
developments express or implied by such forward-looking statements or information. Such factors
include, among others, our stage of development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to
market our products, the ability to protect our intellectual property, dependence on collaborative
partners and the prospects for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and information to differ
materially from any future events or results expressed or implied by such statements and information
include, but are not limited to, the risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we
may not be successful in establishing additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to revise or update such forwardlooking
statements and information to reflect subsequent events or circumstances, except as required
by law.
On Behalf of the Board of Directors
Dr. Mark Day, President and Chief Executive Officer
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release."